^
Association details:
| Biomarker: | EGFR mutation + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
81P - Is PD-1 inhibitor based treatment better than chemotherapy for metastatic NSCLC patients with PD-L1_50% who develop EGFR-TKI resistance? A real-world investigation
Published date:
12/01/2022
Excerpt:
Survival analysis shown that patients who received PD-1 inhibitor based therapies had better PFS and OS compared with those treated with other therapy (median PFS, 4.0 vs. 10.0 months, P＜0.001; median OS, 39.5 vs. 24.2 months, P＜0.001)...patients who treated with PC treatment had a superior survival time than those received PM treatment (median PFS, 10.3 vs. 7.0 months, P＜0.001; median OS, 32.4 vs. 41.6 months, P＜0.001). Subgroup analysis found that the PFS and OS benefit of PC was evident in all subgroups....For advanced NSCLC patients with EGFR mutations and PD-L1 TPS≥50% who have failed prior EGFR-TKI therapies without T790M mutation, PD-1 inhibitor based treatment could provide a more favorable survival than classical chemotherapy.
Secondary therapy:
Chemotherapy
